keyword
MENU ▼
Read by QxMD icon Read
search

leiomyosarcoma therapy

keyword
https://www.readbyqxmd.com/read/28096721/current-concepts-in-non-gastrointestinal-stromal-tumor-soft-tissue-sarcomas-a-primer-for-radiologists
#1
REVIEW
Akshay D Baheti, Jyothi P Jagannathan, Ailbhe O'Neill, Harika Tirumani, Sree Harsha Tirumani
Non-gastrointestinal stromal tumor (GIST) soft tissue sarcomas (STSs) are a heterogeneous group of neoplasms whose classification and management continues to evolve with better understanding of their biologic behavior. The 2013 World Health Organization (WHO) has revised their classification based on new immunohistochemical and cytogenetic data. In this article, we will provide a brief overview of the revised WHO classification of soft tissue tumors, discuss in detail the radiology and management of the two most common adult non-GIST STS, namely liposarcoma and leiomyosarcoma, and review some of the emerging histology-driven targeted therapies in non-GIST STS, focusing on the role of the radiologist...
January 2017: Korean Journal of Radiology: Official Journal of the Korean Radiological Society
https://www.readbyqxmd.com/read/28094040/a-phase-2-study-of-alisertib-mln8237-in-recurrent-or-persistent-uterine-leiomyosarcoma-an-nrg-oncology-gynecologic-oncology-group-study-0231d
#2
David M Hyman, Michael W Sill, Heather A Lankes, Richard Piekarz, Mark S Shahin, Mildred R Ridgway, Floor Backes, Meaghen E Tenney, Cara A Mathews, James S Hoffman, Carol Aghajanian, Martee L Hensley
OBJECTIVE: This two-stage Phase II study assessed the activity of single agent alisertib in patients with recurrent/persistent uterine leiomyosarcoma (uLMS). METHODS: Eligibility criteria included histologically-confirmed, recurrent or persistent uLMS, age≥18, 1-2 prior cytotoxic regimens, and RECIST version 1.1 measurable disease. The primary objective of the study was to evaluate the efficacy of alisertib through the frequency of patients with objective tumor responses and the frequency who survived event-free for at least 6months (EFS6)...
January 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28092017/transanal-total-mesorectal-excision-for-a-large-leiomyosarcoma-at-the-lower-rectum-a-case-report-and-literature-review
#3
Nobuaki Hoshino, Koya Hida, Kenji Kawada, Takaki Sakurai, Yoshiharu Sakai
BACKGROUND: Rectal leiomyosarcoma (LMS) is an extremely rare disease. Previously, LMS was not properly distinguishable from gastrointestinal stromal tumor (GIST) until c-kit, a characteristic marker of GIST, was discovered in 1998. No standard therapeutic strategy for gastrointestinal LMS has been established except for surgical resection because of its rarity. Rectal LMS is often accompanied by symptoms, which can enable detection at a small size. However, when a large LMS is detected at the lower rectum, it is difficult to excise due to the narrow pelvic space...
December 2017: Surgical Case Reports
https://www.readbyqxmd.com/read/28007271/biatrial-high-grade-leiomyosarcoma-with-nine-year-post-surgical-survival
#4
Lakshmi Muthukumar, M Fuad Jan, Robert Taylor, John Crouch, Gary Neitzel, A Jamil Tajik
Primary cardiac leiomyosarcoma is a rare tumor with poor prognosis. We present a 53-year-old female patient with biatrial leiomyosarcoma with inferior vena cava and coronary sinus involvement who underwent aggressive surgical resection with reconstruction of her left and right atrium and coronary sinus with bovine pericardium followed by adjuvant radiation therapy. She is living well with no recurrence 9 years after diagnosis.
January 2017: Annals of Thoracic Surgery
https://www.readbyqxmd.com/read/27955634/transdifferentiation-of-pancreatic-stromal-tumor-into-leiomyosarcoma-with-metastases-to-liver-and-peritoneum-a-case-report
#5
Chao Lin, Liping Wang, Jiyao Sheng, Dan Zhang, Lianyue Guan, Kai Zhao, Xuewen Zhang
BACKGROUND: Primary pancreatic leiomyosarcoma is a rare pancreatic malignancy; the clinical presentation and treatment is not well-characterized. Further, the molecular mechanisms underlying its pathogenesis are not known. We report a patient with pancreatic stromal tumor that progressed to primary pancreatic leiomyosarcoma with hepatic and peritoneal metastases. CASE PRESENTATION: A 54-year-old woman was found to have pancreatic and hepatic tumor masses on routine health checkup...
December 13, 2016: BMC Cancer
https://www.readbyqxmd.com/read/27918201/the-importance-of-treating-by-histological-subtype-in-advanced-soft-tissue-sarcoma
#6
Javier Martín Broto, Axel Le Cesne, Peter Reichardt
While surgical resection (±radiotherapy) is standard treatment for localized soft tissue sarcomas (STS), chemotherapy is the mainstay for managing locally advanced and metastatic disease. Expanding knowledge of the biologies and sensitivities of STS histotypes, in conjunction with results from a growing collection of retrospective reviews and prospective randomized studies, point to the importance of treating in consideration of histological subtype. Doxorubicin ± ifosfamide continues to be standard first-line therapy for most STS subtypes...
January 2017: Future Oncology
https://www.readbyqxmd.com/read/27882721/survival-of-patients-with-metastatic-leiomyosarcoma-the-md-anderson-clinical-center-for-targeted-therapy-experience
#7
Zhijie Wang, Naiyi Shi, Aung Naing, Filip Janku, Vivek Subbiah, Dejka M Araujo, Shreyaskumar R Patel, Joseph A Ludwig, Lois M Ramondetta, Charles F Levenback, Pedro T Ramirez, Sarina A Piha-Paul, David Hong, Daniel D Karp, Apostolia M Tsimberidou, Funda Meric-Bernstam, Siqing Fu
Advanced stage leiomyosarcoma (LMS) is incurable with current systemic antitumor therapies. Therefore, there is clinical interest in exploring novel therapeutic regimens to treat LMS. We reviewed the medical records of 75 consecutive patients with histologically confirmed metastatic LMS, who had been referred to the Clinical Center for Targeted Therapy at MD Anderson Cancer Center. To lay the foundation for potential phase I trials for the treatment of advanced LMS, we analyzed tumor response and survival outcome data...
December 2016: Cancer Medicine
https://www.readbyqxmd.com/read/27867338/bladder-leiomyosarcoma-a-rare-but-aggressive-diagnosis
#8
Mathew Fakhoury, Richard R Hwang, Joseph Silletti, Marc A Bjurlin
It remains evident in the literature that leiomyosarcomas of the bladder have continuously been regarded as highly aggressive tumors associated with a poor prognosis. Immediate surgical therapy by radical cystectomy with wide margins is warranted as an effective treatment modality and has been associated with longer survival rates. Herein, we present the case of a high-grade leiomyosarcoma primarily treated with anterior pelvic exenteration and urinary diversion.
October 2016: Current Urology
https://www.readbyqxmd.com/read/27826698/mr-imaging-of-atypical-fibroids
#9
Candice Bolan, Melanie P Caserta
Leiomyomas are the most common neoplasm found in the uterus and can present with a variety of symptoms or be entirely asymptomatic. Most often, the characteristic imaging appearance of leiomyoma does not pose a diagnostic dilemma. However, leiomyomas can demonstrate atypical imaging features that may be confusing. It is essential for the radiologist to be aware of both the typical and atypical findings to better assist the referring clinician with diagnosis and management decisions. Additionally, as uterine-sparing treatment alternatives with locoregional therapies become more popular, it is important to be aware of pre- and post-procedural imaging questions that may be encountered...
December 2016: Abdominal Radiology
https://www.readbyqxmd.com/read/27821314/multivisceral-resection-of-retroperitoneal-sarcomas-in-the-elderly
#10
H G Smith, J M Thomas, M J F Smith, A J Hayes, D C Strauss
BACKGROUND: Retroperitoneal sarcomas occur in an anatomically complex location often involving several adjacent organs. Surgery with multivisceral resection constitutes the mainstay of curative therapy. This study sought to characterise the morbidity and oncological outcomes of surgery for retroperitoneal sarcoma in an elderly population. METHODS: Patients with primary, localised retroperitoneal sarcoma referred between 1st January 2008 and 31st December 2014 were identified from multidisciplinary meeting records...
November 4, 2016: European Journal of Cancer
https://www.readbyqxmd.com/read/27798858/molecular-pathology-and-novel-clinical-therapy-for-uterine-leiomyosarcoma
#11
REVIEW
Takuma Hayashi, Miki Kawano, Tomoyuki Ichimura, Koichi Ida, Hirofumi Ando, Dorit Zharhary, Yae Kanai, Hiroyuki Aburatani, Susumu Tonegawa, Tanri Shiozawa, Nobuo Yaegashi, Ikuo Konishi
Patients with uterine leiomyosarcoma (LMS) typically present with vaginal bleeding, pain, and a pelvic mass, with atypical presentations of hypercalcemia and eosinophilia also being reported. Radiographic evaluation with combined positron-emission tomography/computed tomography may assist in diagnosis and surveillance in women with uterine LMS; these are commonly used with stage and tumour grade as prognostic indicators and a recently developed risk-assessment index to predict disease-specific survival. Recent studies have shown that the addition of adjuvant therapy after surgical management does not seem to improve survival, and ovarian preservation does not appear to negatively impact outcome...
2016: Anticancer Research
https://www.readbyqxmd.com/read/27775259/major-clinical-research-advances-in-gynecologic-cancer-in-2015
#12
REVIEW
Dong Hoon Suh, Miseon Kim, Hak Jae Kim, Kyung Hun Lee, Jae Weon Kim
In 2015, fourteen topics were selected as major research advances in gynecologic oncology. For ovarian cancer, high-level evidence for annual screening with multimodal strategy which could reduce ovarian cancer deaths was reported. The best preventive strategies with current status of evidence level were also summarized. Final report of chemotherapy or upfront surgery (CHORUS) trial of neoadjuvant chemotherapy in advanced stage ovarian cancer and individualized therapy based on gene characteristics followed...
November 2016: Journal of Gynecologic Oncology
https://www.readbyqxmd.com/read/27771610/a-phase-ii-study-of-tivozanib-in-patients-with-metastatic-and-nonresectable-soft-tissue-sarcomas
#13
M Agulnik, R L B Costa, M Milhem, A W Rademaker, B C Prunder, D Daniels, B T Rhodes, C Humphreys, S Abbinanti, L Nye, R Cehic, A Polish, C Vintilescu, T McFarland, K Skubitz, S Robinson, S Okuno, B A Van Tine
BACKGROUND: Soft tissue sarcomas (STSs) overexpress vascular endothelial growth factors (VEGF) and VEGF-receptors (VEGFR) activation have been associated with tumor aggressiveness. Tivozanib is a potent small molecule tyrosine kinase inhibitor against VEGFR1-3, with activity against PDGFRα/β and cKIT. The primary endpoint of this study was progression free survival (PFS) rate at 16 weeks. Secondary end points were overall survival (OS), response rate, safety and correlative studies...
October 22, 2016: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/27751406/uterine-sarcoma-part-iii-targeted-therapy-the-taiwan-association-of-gynecology-tag-systematic-review
#14
REVIEW
Ming-Shyen Yen, Jen-Ruei Chen, Peng-Hui Wang, Kuo-Chang Wen, Yi-Jen Chen, Heung-Tat Ng
Uterine sarcoma is a very aggressive and highly lethal disease. Even after a comprehensive staging surgery or en block cytoreduction surgery followed by multimodality therapy (often chemotherapy and/or radiation therapy), many patients relapse or present with distant metastases, and finally die of diseases. The worst outcome of uterine sarcomas is partly because of their rarity, unknown etiology, and highly divergent genetic aberration. Uterine sarcomas are often classified into four distinct subtypes, including uterine leiomyosarcoma, low-grade uterine endometrial stromal sarcoma, high-grade uterine endometrial stromal sarcoma, and undifferentiated uterine sarcoma...
October 2016: Taiwanese Journal of Obstetrics & Gynecology
https://www.readbyqxmd.com/read/27733375/short-full-dose-adjuvant-chemotherapy-ct-in-high-risk-adult-soft-tissue-sarcomas-sts-long-term-follow-up-of-a-randomized-clinical-trial-from-the-italian-sarcoma-group-and-the-spanish-sarcoma-group
#15
A Gronchi, S Stacchiotti, P Verderio, S Ferrari, J Martin Broto, A Lopez-Pousa, A Llombart-Bosch, A P Dei Tos, P Collini, J Cruz Jurado, A De Paoli, D M Donati, A Poveda, V Quagliuolo, A Comandone, G Grignani, C Morosi, A Messina, R De Sanctis, S Bottelli, E Palassini, P G Casali, Piero Picci
BACKGROUND: To report on long-term results of a phase 3 trial comparing three versus five cycles of adjuvant chemotherapy (CT) with full-dose epirubicin+ifosfamide in high-risk soft tissue sarcomas (STS). METHODS: Patients (pts) were randomized to receive three preoperative cycles of epirubicin 120 mg/m(2) and ifosfamide 9 g/m(2) (Arm A) or to receive the same three preoperative cycles plus two postoperative cycles (Arm B). Radiotherapy could be either delivered in the preoperative or in the postoperative setting...
December 2016: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/27723066/prevalence-of-cellular-leiomyoma-and-partially-cellular-leiomyoma-in-postoperative-samples-analysis-of-384-cases
#16
Dobrosława L Sikora-Szczęśniak
OBJECTIVES: The aim of the study was to evaluate the prevalence of cellular leiomyomas and partially cellular leiomyomas in postoperative samples. MATERIAL AND METHODS: A total of 2144 cases of uterine leiomyomas were diagnosed in postoperative samples at the Department of Obstetrics and Gynecology, RSzS, Radom, Poland, between 1998 and 2014. We analyzed 384 cases which were subdivided into 4 groups, taking into account the co-occurrence of leiomyomas and/or endometriosis...
2016: Ginekologia Polska
https://www.readbyqxmd.com/read/27721667/molecular-targets-and-emerging-therapeutic-options-for-uterine-leiomyosarcoma
#17
Heather Miller, Chiemeka Ike, Jennifer Parma, Ramya P Masand, Claire M Mach, Matthew L Anderson
Uterine leiomyosarcoma (uLMS) is an aggressive malignancy characterized by its early metastasis, high rates of recurrence, and poor prognosis. Multiple obstacles complicate the clinical management of uLMS. These include the fact that most uLMS are typically identified only after a woman has undergone hysterectomy or myomectomy, the limited efficacy of adjuvant therapy for early stage disease, and the poor response of metastatic disease to current treatments. Here, we discuss recent insights into the molecular basis of uLMS and discuss emerging options for its clinical management...
2016: Sarcoma
https://www.readbyqxmd.com/read/27680058/locoregional-treatment-of-peritoneal-sarcomatosis-a-single-centre-experience
#18
John Spiliotis, Nikolaos Kopanakis, Eleftherios Orestis Argyriou, Evangelos Vafias, Elias Efstathiou
BACKGROUND: Peritoneal sarcomatosis appears to be responding poorly to systemic chemotherapy. Treatment options traditionally include surgical ressections, chemotherapy and radiation therapy. Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) offers a promising alternative locoregional treatment option. PATIENTS AND METHODS: We examine retrospectively 8 patients (4 females, 4 males) with peritoneal sarcomatosis. The most common histology type was the liposarcoma (4/8)...
2016: Annali Italiani di Chirurgia
https://www.readbyqxmd.com/read/27672466/leiomyosarcoma-ex-pleomorphic-adenoma-of-the-parotid-gland-a-case-report-and-literature-review
#19
Michael Coulter, Jingxuan Liu, Mark Marzouk
There is only one previously reported incident in the English literature of sarcoma ex pleomorphic adenoma of the parotid and there are only 8 cases of primary parotid leiomyosarcoma. In our case, a 79-year-old female patient presented to our care with left preauricular pain, swelling, and facial weakness. After CT imaging, she underwent left total parotidectomy. A spindle cell lesion was identified intraoperatively and the facial nerve was sacrificed. Subsequent analysis of the lesion yielded a diagnosis of leiomyosarcoma ex pleomorphic adenoma...
2016: Case Reports in Otolaryngology
https://www.readbyqxmd.com/read/27672333/eribulin-in-the-management-of-inoperable-soft-tissue-sarcoma-patient-selection-and-survival
#20
REVIEW
Colin Thomas, Sujana Movva
Patients diagnosed with metastatic soft-tissue sarcoma (STS) have a poor prognosis. Additionally, after failure of first-line therapy, there are relatively few treatment options from which to choose. The novel tubulin-binding drug, eribulin, with a unique mechanism of action from taxanes or vinca alkaloids, has shown clinical activity in several different types of cancers. Eribulin has been approved by the US Food and Drug Administration (FDA) for patients with metastatic breast cancer previously treated with an anthracycline or a taxane and has recently been FDA approved for patients with unresectable or metastatic liposarcoma who have failed a previous anthracycline regimen...
2016: OncoTargets and Therapy
keyword
keyword
115503
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"